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STRUCTURED ABSTRACT 
AIMS: To compare microvascular and macrovascular complication rates among Ghanaians 
with type 2 diabetes (T2D) living in Ghana and in three European cities (Amsterdam, London 
and Berlin).  
METHODS: Data from the multicenter Research on Obesity and Diabetes among African 
Migrants (RODAM) study were analyzed. 650 Ghanaian participants with T2D (206 non-
migrant and 444 migrants) were included. Logistic regression analyses were used to 
determine the association between migrant status and microvascular (nephropathy and 
retinopathy) and macrovascular (coronary artery disease (CAD), peripheral artery disease 
(PAD) and stroke) complications with adjustment for age, gender, socioeconomic status, 
alcohol, smoking, physical activity, hypertension, BMI, total-cholesterol, and HbA1c.  
RESULTS: Microvascular and macrovascular complications rates were higher in non-
migrant Ghanaians than in migrant Ghanaians (nephropathy 32.0% vs. 19.8%; PAD 11.2% 
vs. 3.4%; CAD 18.4% vs. 8.3%; and stroke 14.5% vs. 5.6%), except for self-reported 
retinopathy (11.0% vs. 21.6%). Except nephropathy and stroke, the differences persisted after 
adjustment for the above-mentioned covariates: PAD (OR 7.48; 95%CI, 2.16-25.90); CAD 
(2.32; 1.09-4.93); and retinopathy (0.23; 0.07-0.75). 
CONCLUSIONS: Except retinopathy, the rates of microvascular and macrovascular 
complications was higher in non-migrant than in migrant Ghanaians with T2D. Conventional 
cardiovascular risk factors did not explain the differences except for nephropathy and stroke.  
KEYWORDS: Diabetes complications, microvascular, macrovascular, Ghana, RODAM 
study, ethnic minority groups. 
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1. INTRODUCTION  
Worldwide, the prevalence of diabetes is increasing, but substantial variations exist between 
regions (1). According to the International Diabetes Federation in 2017, about 16 million 
people in sub-Saharan Africa had diabetes, with the burden projected to increase to 41 
million people by 2045, the highest projected increase anywhere in the world (2). 
Diabetes increases the risk of macrovascular disease, including coronary heart disease 
(CAD), peripheral vascular disease (PAD), and stroke (3,4). Diabetes also causes specific 
microvascular complications such as retinopathy, nephropathy and neuropathy, and remains a 
leading cause of blindness, end stage kidney disease, and lower limb amputation (3,5–8). The 
microvascular and macrovascular complications of diabetes contribute to reduced quality of 
life, increased risk of hospitalization, disability and mortality, that pose a burden on the 
economies of all countries, especially the low and middle income ones (9,10).   
In high-income countries, migrant populations including those from sub-Saharan Africa are 
disproportionately affected by diabetes, and tend to develop the disease at a younger age than 
the host populations (11). For example, the prevalence of type 2 diabetes was two to three 
times higher in populations of sub-Saharan Africa origin than in European host populations 
(11). Further, migrants resident in high-income countries have higher prevalence of diabetes 
than their counterparts in rural sub-Saharan Africa (12). These disparities may suggest a role 
of environmental factors in the development of diabetes among these populations (12).  
In a previous Research on Obesity & Diabetes among African Migrants (RODAM) study, we 
observed higher diabetes prevalence in migrant-Ghanaians in three European cities compared 
to non-migrant Ghanaians (12). The prevalence of diabetes-related microvascular and 
macrovascular complications in the two populations, however, is not known. Therefore, we 
assessed the prevalence of microvascular (nephropathy and retinopathy) and macrovascular 
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(CAD, PAD and stroke) complications in the RODAM cohorts with type 2 diabetes in 
Europe and in Ghana. Furthermore, we assessed whether the rates of diabetic microvascular 
and macrovascular complications vary between Ghanaian migrants in Europe and their non-
migrant compatriots living in Ghana.  
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2. METHODS 
2.1 Study Design 
The rationale, conceptual framework, design and methodology of the RODAM study have 
been described in detail elsewhere (13). For the current analysis only participants with type 2 
diabetes were included in the analyses. This included data from 206 participants in Ghana 
and 444 Ghanaian migrants resident in Amsterdam, Berlin and London (figure 1). Type 2 
diabetes was defined according to the World Health Organization diagnostic criteria (self-
reported diabetes, documented use of glucose-lowering medication(s), fasting plasma 
glucose ≥ 7.0 mmol/L) or HbA1c ≥ 6.5% or ≥48 mmol/mol (14). Participants who met the 
diagnostic criteria for diabetes but who had no prior diabetes and who were not on glucose-
lowering medication(s) were considered to have undiagnosed diabetes.  
 
2.2 Participants’ Baseline Measurements 
A structured questionnaire (13) was used to record the demographic, socioeconomic, health-
related behaviors, and microvascular and macrovascular complications (retinopathy, CAD, 
and strokes) of the study participants. The assessment of educational status was adapted to 
local circumstances at the different study sites and comprised four categories: never been to 
school or elementary school; lower vocational schooling or lower secondary schooling; 
intermediate vocational schooling or intermediate/higher secondary schooling; and higher 
vocational schooling or university. Smoking was assessed as a positive reply to the question 
‘Do you smoke at all?’ Alcohol intake in grams per day was estimated using standard portion 
seizes combined with frequencies of intake based on a standardised Food Propensity 
Questionnaire. Physical activity was derived for each participant using International physical 
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activity questionnaire (15). Respondents were classified into three categories of total physical 
activity, namely low, moderate and high level. Eyesight was graded by the response to the 
question ‘At the present time, would you say your eyesight using both eyes (with glasses or 
contact lenses, if you wear them) is excellent, good, fair, poor, or very poor or are you 
completely blind?’  
Physical examinations were performed with validated devices according to standardized 
operational procedures across all study sites. Weight was measured in light clothing and 
without shoes with SECA 877 scales to the nearest 0.1 kg. Height was measured without 
shoes with a portable stadiometer (SECA 217) to the nearest 0.1 cm. Body mass index (BMI) 
was calculated as weight (kg) divided by height squared (m
2
). Waist circumference (WC) was 
measured in centimeters at the midpoint between the lower margin of the least palpable rib 
and the top of the iliac crest. Hip circumference (HC) was measured in centimeters around 
the widest portion of the buttocks, at the level of the greater trochanters, with the tape parallel 
to the floor. Waist-to-hip ratio (WHR) was determined as the ratio of WC to HC. All the 
anthropometrics were measured twice by the same assessor and the average of the two 
measurements was used for analyses. Body fat was determined using arm-leg bio-impedance 
measurements using a Bodystat 1500 analyzer (Bodystat Ltd, Isle of Man, UK). The body fat 
percentage was calculated using the African-specific formula by Kyle et al. (16) 
Blood pressure (BP) was measured three times using a validated semi-automated device 
(Microlife Watch BP home, Widnau, Switzerland), with appropriate sized cuffs after at least 
5 minutes rest while seated. The mean of the last two BP measurements was used for the 
analyses. Hypertension was defined as systolic BP ≥140 mmHg and/or diastolic 
BP ≥90 mmHg, and/or being on antihypertensive medication treatment. Ankle brachial index 
(ABI), the ratio of the resting systolic blood pressure at the ankle to the resting systolic 
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brachial pressure at the arm, was obtained from two blood pressure measurements on the left 
side (leg and arm) and two on the right side (leg and arm) using the Microlife Watch BP 
Office ABI with appropriate sized cuffs, after at least 10 minutes of supine rest. The cuffs for 
measuring the ankle and brachial pressures were placed just above the ankle and at the upper 
arm, respectively. 
 
2.3 Biochemical Analyses 
Fasting venous blood samples were processed and aliquoted into Sarstedt tubes after 
collection according to standard operation procedures, and then temporarily stored at the 
local research location at −20 °C. Two aliquoted blood samples and one first early morning 
urine sample were transported to the local research centres, where they were checked, 
registered and stored at −80 °C before being shipped to the laboratory at Charité–University 
Medicine Berlin (Berlin, Germany) for determination of biochemical variables. Shipping of 
the samples from European sites was carried out using Styrofoam boxes filled with dry ice 
and from Ghana in dry shippers filled with liquid nitrogen. Extensive quality checks were 
done during the biochemical analysis, including blinded serial measurements. 
Fasting glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides levels 
were determined using the ABX Pentra 400 chemistry analyzer (HORIBA ABX, Montpellier, 
France). Fasting plasma glucose concentration was measured using an enzymatic method 
(hexokinase). Concentration of total cholesterol was assessed by using colorimetric test kits.. 
HbA1c was measured by high-performance liquid chromatography (TOSOH G8 HPLC 
analyzer). Serum creatinine concentration was determined by a kinetic colorimetric 
spectrophotometric isotope dilution mass spectrometry calibration method (Roche 
Diagnostics). Estimated glomerular filtration rate (eGFR) was calculated using the 2009 
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CKD-EPI (CKD Epidemiology Collaboration) creatinine equation and the severity of kidney 
disease categorized according to the 2012 KDIGO guidelines (17). 
Urinary albumin concentration (in mg/L) was measured by an immunochemical turbidimetric 
method (Roche Diagnostics). Urinary creatinine concentration (in μmol/L) was measured by 
a kinetic spectrophotometric method (Roche Diagnostics). Urinary albumin–creatinine ratio 
(ACR; expressed in mg/g) was calculated by taking the ratio between urinary albumin and 
urinary creatinine and stratified according to the 2012 KDIGO classifications: A1, <3 
mg/mmol (normal to mildly increased); A2, 3 to 30 mg/mmol (moderately increased); and 
A3, > 30 mg/mmol (severely increased).  
 
2.4 Determination of Microvascular and Macrovascular Complications  
Nephropathy was defined as albuminuria or microalbuminuria based on the report from Joint 
Committee on Diabetic Nephropathy (18). PAD was defined as ankle brachial index <0.9 
(19). Retinopathy was assessed by a positive reply to the question ‘Have you ever been told 
by a doctor or health care worker that you have eye disease or eye damage as a result of your 
diabetes (diabetic retinopathy)?’ (13). Coronary artery disease (CAD) was assessed using the 
WHO Rose angina questionnaire (20). Possible myocardial infarction was defined as a 
positive reply to the question ‘have you ever had a severe pain across the front of your chest 
lasting for half an hour or more?’ Angina was defined as a positive reply to the questions 
‘Have you ever had any pain or discomfort in your chest?’ and ‘Do you get this pain or 
discomfort when you walk uphill or hurry?’ Stroke was assessed by a positive reply to the 
question ‘Have you ever had a stroke?’ (13). 
 
2.5 Statistical Analysis 
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Data were analyzed using the IBM SPSS version 22 for Windows. Data with normal 
distribution was presented as mean ± standard deviation whereas those not normally 
distributed presented as median (interquartile range). Categorical data were presented as 
frequencies (percentages). Differences in demographic, clinical and micro- and 
macrovascular function between migrants and non-migrants with type 2 diabetes were 
assessed by chi-square test or two-sample independent sample t-test for categorical or 
continuous covariates, respectively.  
Multivariable logistic regression was used to build a model of factors associated with the 
microvascular and macrovascular complications including nephropathy, retinopathy, CAD, 
PAD, and stroke (dependent variables); and the sites of residence in Ghana and Europe 
(independent variable) with adjustments for potential covariates. Four models were used to 
examine the data: model 1 was unadjusted for any covariate; model 2 was adjusted for age 
and gender; model 3 was additionally adjusted for socioeconomic status (level of education); 
and model 4 was additionally adjusted for the conventional cardiovascular risk factors 
including, smoking; physical activity, hypertension, BMI, hypercholesterolemia, HbA1c and 
amount of alcohol consumed. he data as presented as odds ratios (OR) with their 
corresponding 95% confidence intervals (CI). The analyses were performed for Ghanaian and 
European sites using Europe as reference. In a sensitivity analysis, we further compared the 
proportions of microvascular and macrovascular complications between migrant and non-
migrant Ghanaians stratified by previously known and unknown diabetes. A statistical test of 
significance was set at p-value < 0.05.   
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3. RESULTS  
3.1 General Characteristics 
The baseline characteristics for the migrants and non-migrants with type 2 diabetes are 
described in table 1. Although there was no difference in age, migrants were more frequently 
male than non-migrants. Migrants generally had a higher level of education, had a higher 
proportion of current smokers, and consumed more alcohol than their non-migrant 
counterparts. While there was no difference in the percent body fat between the two groups, 
the BMI and WHR were higher in the migrant group than in non-migrants. There was no 
difference in the duration of diabetes between migrants and non-migrants. The systolic blood 
pressure and diastolic blood pressure were also higher in the migrant group than in non-
migrants. However, the non-migrant group had a higher proportion of undiagnosed diabetes, 
lower proportion of participants taking glucose lowering medications, poorer glycemic 
control and worse eyesight compared to migrants. Additionally, non-migrants had higher 
concentrations of blood triglyceride and LDL-cholesterol and lower HDL-cholesterol 
concentration than migrants. 
 
3.2 Differences in microvascular and macrovascular complications between migrants 
and non-migrants  
Table 2 shows the differences in the prevalence of microvascular and macrovascular 
complications between the migrant and non-migrant Ghanaians with type 2 diabetes. Overall, 
the proportion of nephropathy was higher in non-migrants than in migrants (32.0% vs. 
19.8%). Additionally, non-migrants were more likely to have moderate to severe forms of 
albuminuria (categories A2 and A3; ACR >3 mg/mmol). There was no difference in the 
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eGFR categories between the two groups. Non-migrants also had higher prevalence of PAD 
(11.2% vs. 3.4%), CAD (18.4% vs. 8.3%) and s stroke (14.5% vs. 5.6%) than migrants. 
However, migrants had higher prevalence of self-reported diabetic retinopathy previously 
diagnosed by a doctor or health worker than non-migrants (21.6% vs. 11.0%).  
The odds ratios (ORs) of the microvascular and macrovascular complications for Ghanaians 
with type 2 diabetes living in rural and urban Ghana compared with Ghanaians living in the 
three European cities are shown in table 3. After adjusting for age and gender, living in 
Ghana was still associated with higher odds for developing nephropathy (OR 2.01, 95% CI, 
1.35-3.01), PAD (OR 3.14, 95% CI, 1.58-6.24), CAD (OR 2.31, 95% CI, 1.40-3.83) and 
stroke (OR 2.74, 95% CI, 1.52-4.93). Similar results were obtained after additionally 
adjusting for socioeconomic status. However, after further adjustments for the conventional 
cardiovascular risk factors, the proportion of the nephropathy and self-reported strokes was 
no longer statistically significant, but the differences persisted for the macrovascular 
complications PAD (OR 7.48, 95% CI, 2.16-25.90) and CAD (OR 2.32, 95% CI, 1.09-4.93). 
Adjustment for age, gender and socioeconomic status explained the differences in retinopathy 
diagnosed by a doctor.  
The prevalence rates of microvascular and macrovascular complications were generally 
similar between newly diagnosed diabetes and established diabetes participants 
(Supplementary Table 1). When the analysis was further stratified by participants with 
previously known diabetes and undiagnosed diabetes (Supplemental Table 2), the proportions 
of nephropathy (35.8% vs. 17.1%, p<0.001), PAD (10.6% vs. 4.3%, p=0.028) and CAD 
(20.8% vs. 8.4%, p=0.001) were higher, but self-reported diabetic retinopathy (11.0% vs. 
22.2%, p=0.022) was lower in non-migrants than in migrants among previously known 
diabetes participants. For participants with undiagnosed diabetes, the proportions of 
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nephropathy, CAD and PAD were similarly higher in non-migrants than in migrants although 
the differences were not significant except for PAD (12.0% vs. 1.9%, p=0.002).  
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4. DISCUSSION 
4.1 Key findings 
Our study shows that the prevalence of both microvascular (nephropathy) and macrovascular 
(coronary artery disease, peripheral artery disease and self-reported stroke) complications are 
higher in non-migrant than in migrant-Ghanaians with type 2 diabetes. Correction for 
conventional cardiovascular risk factors attenuated differences in the complication rates. 
However, after correction for conventional cardiovascular risk factors, the difference in PAD 
and CAD remained statistically significant.  
 
4.2 Discussion of key findings 
There is limited published data on community level of diabetes-related microvascular and 
macrovascular complications among sub-Saharan Africans with type 2 diabetes. Most studies 
are either diabetes clinic-based or hospital-based surveys (21–26). Moreover, on account of 
differences in study methodology and diagnostic criteria used in defining the diabetes-related 
microvascular and macrovascular complications, reports show wide variations (21–27). With 
the exception of CAD, our findings for non-migrant Ghanaians with type 2 diabetes compare 
well with these studies. The differences in the proportion of CAD could be due to the 
diagnostic criteria for CAD used in previous studies (26). In the study on coronary heart 
disease in the diabetic African, Touze et al. assessed CAD via stress test and/or coronary 
arteriography (26). In this study, we evaluated CAD using the WHO Rose angina 
questionnaire. The WHO Rose angina questionnaire has been shown to overestimate CAD 
prevalence, with higher sensitivity among people from lower socio-economic status (28,29). 
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This could explain the relatively higher prevalence of CAD observed in non-migrant 
Ghanaians with type 2 diabetes, compared with the findings from Touze et al.  
Published studies comparing the burden of microvascular complications in sub-Saharan 
Africans with type 2 diabetes and their migrant counterparts are limited. Choukem et al.  
previously compared microvascular complications between Cameroonians with type 2 
diabetes living in Cameroon and those who migrated to France (30). After adjusting for the 
conventional cardiovascular risk factors, Cameroonians with type 2 diabetes living in 
Cameroon were found to have a 5.6 higher odds of nephropathy than their counterparts living 
in France (30). Although less marked compared with the findings by Choukem et al., this 
present study shows that non-migrant Ghanaians had higher prevalence of nephropathy than 
migrants. Our non-migrant participants with type 2 diabetes had better glycemic control than 
the non-migrant Cameroonians studied by Choukem et al.  This could explain why we had 
less marked differences in the prevalence of nephropathy between migrant and non-migrant 
Ghanaians with type 2 diabetes.  
Contrary to the other microvascular and macrovascular complications, retinopathy diagnosed 
by a doctor or health worker was higher in migrants than in non-migrants. This may reflect 
the better access to healthcare by migrants and hence increased likelihood of diagnosis of the 
complication. Therefore, retinopathy assessed this way may reflect diagnosis of the 
complication by a doctor or healthcare worker instead of true prevalence of the disease. In 
this study, when participants were asked to grade their eyesight as excellent, good, fair, poor, 
or very poor or completely blind, in contrast to the retinopathy previously diagnosed by a 
doctor or healthcare worker, non-migrant Ghanaians were more likely to report poor vision to 
total blind compared with their migrant peers. This highlights the need for more objective 
measures such as fundus photography in making diagnoses of retinopathy.  
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With the exception of factors related to glycemic control and blood lipids, living in Europe 
was associated with a worse cardiovascular risk profile in Ghanaians with type 2 diabetes. 
This is consistent with findings from previous studies that have compared cardiovascular 
disease risk factors among residents with or without type 2 diabetes living in rural and 
urbanized cities in their respective countries or overseas (31,32). Using data from the 
RODAM study, we have previously reported that European residence was associated with 
higher odds for elevated 10-year risk of cardiovascular disease among Ghanaian men with or 
without diabetes (33). It is thus interesting to observe that despite their overall poorer 
cardiovascular risk profiles, migrants had lower complication rates than their non-migrant 
counterparts. Therefore, poor glycemic control (evidenced by the higher HbA1c in non-
migrant Ghanaians), instead of the other conventional cardiovascular risk factors, could be 
the key driving force for the development of these diabetic microvascular complications. This 
supports the existing pathophysiological explanation for microvascular injury that highlights 
chronic hyperglycemia as the central mechanism (34). Further, it underscores the importance 
of glycemic control in preventing diabetes-related complications and the need for 
implementation of strategies to improve glycemic control among people with diabetes in 
Ghana. 
Although the higher prevalence of microvascular and macrovascular complications in non-
migrant Ghanaians is likely to reflect poorer diabetes care, it remains unclear whether the 
observed differences is due to differences in the access to quality care or related to the 
microvascular and macrovascular complications rates at the time of diagnosis. While this 
study did not directly address the impact of healthcare on the development of microvascular 
and macrovascular complications, it is conceivable that access to healthcare and timely 
initiation of medical treatment could explain some of the differences. The attenuation of 
differences in microvascular and macrovascular complications after correction for 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
17 
 
conventional cardiovascular risk factors is supportive of this assumption. Indeed a previous 
report from Ghana had indicated limited health infrastructure and access for diabetes care 
(35). In people with diabetes, both lack of health care coverage and low utility of available 
health care service are known to be associated with poor glycemic control (36).  
In this study, we observed a higher proportion of undiagnosed diabetes in non-migrants 
compared to migrants. However, the microvascular and macrovascular complication rates in 
the undiagnosed and previously diagnosed diabetes groups were similar. Given the above 
facts, the higher proportion of undiagnosed diabetes in the non-migrant group may not 
explain all the observed differences in the complication rates between migrant and non-
migrant Ghanaians with type 2 diabetes. Thus, just improving targeted screening for type 2 
diabetes without appropriate treatment and management of complications may not necessarily 
decrease the rates of diabetes-related microvascular and macrovascular complications.  
Therefore care of diabetes after diagnosis as well as controlling the modifiable risk factors for 
vascular complications may play important roles in reducing the rates and severity of 
diabetes-related microvascular and macrovascular complications. This is evidenced by the 
lower rates of complications in migrants who reside in Europe where diabetes is likely to be 
diagnosed earlier and complication screening and care instituted. Previous studies have 
shown that the asymptomatic phase of type 2 diabetes (lasting at least 4 to 7 years) is known 
to be associated with increased risk of developing microvascular complications (37). 
Additionally, early diagnosis and treatment of hyperglycemia is known to prevent disease 
progression and delay the development of diabetes related complications (38). 
Although the strength of association between migrant status and diabetes complications differ 
in the subgroups with unknown diabetes and previously known diabetes, the pattern of 
associations are similar. This may imply that aside hyperglycemia, other risk factors may be 
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important in driving development of diabetic microvascular and macrovascular 
complications. In this study, we observed higher LDL-cholesterol concentrations and lower 
HDL-cholesterol concentrations in non-migrants compared to migrant Ghanaians. Diabetic 
dyslipidemia is known to cause or exacerbate diabetic microvascular and macrovascular 
complications via multiple mechanisms including alterations in the coagulation-fibrinolytic 
system, changes in membrane permeability, damage to endothelial cells and increased 
atherosclerosis (39) 
Diabetic microvascular and macrovascular complications have similar etiologic 
characteristics, with chronic hyperglycemia driving several metabolic and structural 
derangements including the formation of advanced glycation end products, activation of 
inflammatory pathways, and increased oxidative stress (34). Further, diabetics 
with microvascular complications are prone to accelerated atherosclerosis and subsequent 
macrovascular injury (34). It would, therefore, have been expected that the risk factors 
driving microvascular injury and atherosclerosis would explain the differences in the 
prevalence of macrovascular complications in our cohort. However, adjusting for these risk 
factors could not explain the differences in PAD and CAD suggesting that other unmeasured 
factors may play a role. It is worth noting that the time dependent effects of blood pressure, 
poor glycemic control and persistent dyslipidemia on microvascular and macrovascular 
complications were not assessed in this study due to the cross-sectional design nature of our 
study. More work is needed to identify other potential factors driving the differences in 
macrovascular complications among migrant and non-migrant Ghanaians. This could 
possibly inform complication prevention strategies and treatment efforts. 
 
4.3 Strengths and limitations  
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Key strengths of our study are that we used a relatively homogenous multi-centered study 
population of Ghanaians and well-standardized study protocols across the various study sites. 
Additionally, we eliminated the limitation of intra-laboratory variability by using the same 
standard operating procedures in the same laboratory for running all samples across all sites. 
Our study is limited in a number of ways. First, we used both objective and subjective 
measures for microvascular and macrovascular complications, but both pointed to the same 
direction. We assessed CAD via the Rose Angina Questionnaire. Although the Rose Angina 
Questionnaire has moderate sensitivity, it has a high specificity to detect CAD and is valuable 
for screening individuals at risk of CAD in large-scale epidemiological surveys (28). CAD 
and stroke were self-reported, which could have led to reporting bias. While the question 
used to assess diabetic retinopathy is a very sensitive measure for proliferative retinopathy 
and has a high specificity for measuring the prevalence of diabetic retinopathy, it is less 
sensitive for non-proliferative retinopathy (40). Additionally, neuropathy, another 
microvascular complication, was not assessed. Finally, the duration of diabetes was not 
included as a covariate in the multivariable analysis because a large number of study 
participants did not provide this information. 
 
4.4 Conclusion 
Our study shows that Ghanaian migrants with T2D had lower prevalence of microvascular 
and macrovascular complications than their non-migrant counterparts. Unlike the CAD and 
PAD, the differences in the nephropathy and stroke were explained by poorer glycemic 
control in non-migrant Ghanaians. Therefore, the higher prevalence of microvascular 
complications in non-migrants is likely to reflect poorer diabetic care.  Thus, interventions 
aimed at improving glycemic control among non-migrant Ghanaians may help to reduce the 
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prevalence of some diabetic microvascular and macrovascular complications in Ghana. More 
work is needed to identify potential factors driving the high prevalence of microvascular and 
macrovascular complications among non-migrant Ghanaians to assist the prevention and 
treatment efforts. 
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Table 1: Baseline characteristics of subjects  
 Migrants
*
     Non-migrants
†
 p value 
 Migrants     Non-migrants p value 
Participants  n=444 n=206  
Female gender 222 (50.0%) 142 (68.9%)  <0.001 
Age (y) 52.22 (±8.83) 52.86 (±9.99) 0.408 
Education   <0.001 
   None or elementary 103 (24.8%) 96 (48.2%)  
   Lower secondary 159 (38.2%) 70 (35.2%)  
   Higher secondary 97 (23.3%) 25 (12.6%)  
   Tertiary education 57 (13.7%) 8 (4.0%)  
Physical activity 
 
  0.217 
   Low level 118 (34.8%) 82 (41.2%)  
   Moderate level 74 (21.8%) 44 (22.1%)  
   High level 147 (43.4%) 73 (36.7%)  
Eyesight    0.011 
   Excellent 37 (10.6%) 8 (4.0%)  
   Good 159 (45.4%) 78 (39.0%)  
   Fair 125 (35.7%) 88 (44.0%)  
   Poor 28 (8.0%) 23 (11.5%)  
   Very poor 1 (0.3%) 2 (1.0%)  
   Completely blind 0 (0.0%) 1 (0.5%)  
Body Fat Percentage (%) 33.49 (±8.88) 32.41 (±8.24) 0.164 
BMI, kg/m
2
  30.42 (±5.36) 26.92 (±5.94) <0.001 
Waist-to-hip ratio 0.95 (±0.07) 0.94 (±0.06) 0.016 
Current smokers (%) 18 (4.3%) 0 (0.0%) 0.009 
Consume alcohol, % 210 (73.4%) 110 (53.9%) <0.001 
Alcohol consumed, g/day 1.65 (7.48) 0.06 (0.61) <0.001 
Systolic BP, mmHg 140.43 (±17.38) 133.58 (±21.81) <0.001 
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Diastolic BP, mmHg 85.97 (±10.56) 82.47 (±11.69) <0.001 
Diagnosis of Hypertension  364 (82.0%) 128 (62.1%) <0.001 
Duration of Diabetes (y) 5.00 (8.00) 3.00 (7.00) 0.053 
Undiagnosed diabetes   158 (35.6%) 100 (48.5%) 0.002 
Glucose-lowering medications  197 (44.4%) 50 (24.3%) <0.001 
Blood glucose, mmol/L 7.34 (±3.64) 9.99 (±4.75) <0.001 
HbA1c, mmol/mol 55.11 (±17.73) 67.76 (±28.86) <0.001 
Total cholesterol, mmol/l 4.99 (±1.31) 5.52 (±1.24) <0.001 
Triglycerides, mmol/l 1.08 (±0.59) 1.56 (±0.84) <0.001 
LDL-cholesterol, mmol/l 3.16 (±1.16) 3.62 (±1.10) <0.001 
HDL-cholesterol, mmol/l 1.34 (±0.33) 1.19 (±0.35) <0.001 
 
Values for categorical variables are given as number (percentage); for continuous variables, 
as mean (±standard deviation) or median (interquartile range). Definition of abbreviations:  
BMI = Body mass index; BP = Blood pressure; bpm=beats per minute; HbA1c = 
Glycosylated Hemoglobin; HDL = High-density lipoprotein; LDL = Low-density lipoprotein.  
*Ghanaian residents living in Europe; 
†
 Ghanaian residents living in Ghana 
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Table 2: Microvascular and Macrovascular Complications among migrants and non-
migrants   
 
 Migrants
*
     Non-migrants
†
 p value 
Participants  n=444 n=206  
CKD-EPI eGFR, mL/min/1.73 
m
2
 
90.8 (±19.0) 90.2 (±20.7) 0.708 
CKD-EPI eGFR categories    0.219 
    G1 and G2 393 (94.7%) 189 (92.2%)  
    G3 – G5 22 (5.3%) 16 (7.8%)  
Albuminuria category   <0.001 
   A1, normal: <3 mg/mmol 382 (88.6%) 150 (73.9%)  
   A2, moderate: 3-30 
mg/mmol 
41 (9.5%) 46 (22.7%)  
   A3, severe: >30 mg/mmol 8 (1.9%) 7 (3.4%)  
Nephropathy  88 (19.8%) 66 (32.0%) 0.001 
Retinopathy  38 (21.6%) 11 (11.0%) 0.033 
ABI  1.20 (±0.11) 1.11 (±0.11) <0.001 
PAD 15 (3.4%) 23 (11.2%) <0.001 
CAD  37 (8.3%) 38 (18.4%) <0.001 
Stroke 23 (5.6%) 29 (14.5%) <0.001 
 
Values for categorical variables are given as number (percentage); for continuous variables, 
as mean (±standard deviation) or median (interquartile range).  
Definition of abbreviations:  ABI, Ankle Brachial Index; ACR, Albumin-creatinine ratio; 
CKD-EPI, Chronic Kidney Disease - Epidemiology Collaboration; eGFR, estimated 
glomerular filtration rate; PAD, Peripheral Artery Disease 
*Ghanaian residents living in Europe; 
†
 Ghanaian residents living in Ghana 
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Table 3: Multivariable logistic regression models for nephropathy, retinopathy, PAD, CAD and strokes among Ghanaians living in Ghana and Ghanaians living in Europe (reference = Europe) (n = 603) 
 
 Model 1 Model 2 Model 3 Model 4 
OR 95% C.I P OR 95% C.I p  OR 95% C.I P OR 95% C.I P 
 Lower Upper    Lower Upper     Lower Upper    Lower Upper   
Nephropathy  1.85 1.26 2.73 0.002 2.01 1.35 3.01 0.001  2.03 1.34 3.07 0.001 1.41 0.80 2.50 0.232 
Retinopathy  0.44 0.21 0.92 0.028 0.40 0.19 0.85 0.017  0.47 0.22 1.02 0.055 0.23 0.07 0.75 0.014 
PAD 3.42 1.74 6.71 <0.001 3.14 1.58 6.24 0.001  2.72 1.34 5.53 0.006 7.48 2.16 25.90 0.010 
CAD 2.29 1.40 3.74 <0.001 2.31 1.40 3.83 0.001  2.22 1.32 3.74 0.003 2.32 1.09 4.93 0.029 
Stroke 2.85 1.60 5.07 <0.001 2.74 1.52 4.93 0.001  2.66 1.45 4.91 0.002 1.45 0.42 5.00 0.553 
 
Definition of abbreviations:  CAD = Coronary artery disease; CI = Confidence interval; OR = odds ratio; PAD = Peripheral arterial disease. 
Model 1 – unadjusted for covariates 
Model 2 – adjusted for age and gender  
Model 3 – adjusted for age, gender, and socioeconomic status  
Model 4 – adjusted for age, gender, socioeconomic status, alcohol consumption, smoking; physical activity, hypertension, BMI, total cholesterol, and HbA1c 
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Online-only supplemental table 1: Microvascular and Macrovascular Indices among 
newly-diagnosed diabetes patients and previously known diabetes 
 
 Undiagnosed 
Diabetes 
Previously known 
diabetes  
p value 
 N = 258 N = 392  
CKD-EPI eGFR, mL/min/1.73 
m
2
 
92.01 (±19.23) 89.72 (±19.74) 0.154 
CKD-EPI eGFR categories    0.332 
    G1 and G2 236 (91.5%) 346 (88.3%)  
    G3 – G5 11 (4.3%) 27 (6.9%)  
Albuminuria category   0.925 
   A1, normal: <3 mg/mmol 209 (81.0%) 323 (82.4%)  
   A2, moderate: 3-30 mg/mmol 36 (14.0%) 51 (13.0%)  
   A3, severe: >30 mg/mmol 7 (2.7%) 8 (2.0%)  
Nephropathy  67 (26.0%) 87 (22.2%) 0.300 
ABI  1.16(±0.11) 1.18 (±0.12) 0.016 
PAD  15 (5.8%) 23 (5.9%) 0.532 
CAD  29 (11.2%) 46 (11.7%) 0.901 
Stroke 25 (10.7%) 27 (7.1%) 0.137 
 
Values for categorical variables are given as number (percentage); for continuous variables, 
as mean (±standard deviation) or median (interquartile range).  
Definition of abbreviations:  ABI, Ankle Brachial Index; ACR, Albumin-creatinine ratio; 
CKD-EPI, Chronic Kidney Disease - Epidemiology Collaboration; eGFR, estimated 
glomerular filtration rate; PAD = peripheral artery disease 
 
 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PTE
D M
AN
US
CR
IPT
Online-only supplemental table 2: Microvascular and Macrovascular complications among migrants and non-migrants with previously diagnosed diabetes and 
undiagnosed diabetes.  
 Previously Known Diabetes  Undiagnosed Diabetes  
 Migrants
*
     Non-migrants
†
 p value Migrants
*
     Non-migrants
†
 p value 
 n=286 n=106  n=158 n=100  
CKD-EPI eGFR, mL/min/1.73 m
2
 90.7 (±19.0) 87.2 (±21.4) 0.124 91.1 (±19.0) 93.4 (±19.7) 0.361 
CKD-EPI eGFR categories    0.180   0.761 
    G1 and G2 252 (94.0%) 94 (89.5%)  141 (95.9%) 95 (95.0%)  
    G3 – G5 16 (6.0%) 11 (10.5%)  6 (4.1%) 5 (5.0%)  
Albuminuria category   <0.001   0.225 
   A1, normal: <3 mg/mmol 251 (90.0%) 72 (69.9%)  131 (86.2%) 78 (78.0%)  
   A2, moderate: 3-30 mg/mmol 23 (8.2%) 28 (27.2%)  18 (11.8%) 18 (18.0%)  
   A3, severe: >30 mg/mmol 5 (1.8%) 3 (2.9%)  3 (2.0%) 4 (4.0%)  
Nephropathy  49 (17.1%) 38 (35.8%) <0.001 39 (24.7%) 28 (28.0%) 0.563 
Retinopathy  38 (22.2%) 11 (11.0%) 0.022 - - - 
ABI  1.21 (±0.11) 1.11 (±0.11) <0.001 1.19 (±0.10) 1.11 (±0.11) <0.001 
PAD 12 (4.3%) 11 (10.6%) 0.028 3 (1.9%) 12 (12.0%) 0.002 
CAD  24 (8.4%) 22 (20.8%) 0.001 13 (8.2%) 16 (16.0%) 0.068 
Stroke 10 (3.7%) 8 (7.5%) 0.176 2 (1.4%) 5 (5.3%) 0.120 
Values for categorical variables are given as number (percentage); for continuous variables, as mean (±standard deviation) or median (interquartile range).  
Definition of abbreviations:  ABI, Ankle Brachial Index; ACR, Albumin-creatinine ratio; CKD-EPI, Chronic Kidney Disease - Epidemiology Collaboration; eGFR, estimated 
glomerular filtration rate; PAD, Peripheral Artery Disease 
*Ghanaian residents living in Europe; 
†
 Ghanaian residents living in Ghana
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Highlights 
 African migrants in Europe have higher rates of diabetes than their non-migrants peers. 
 Migrants with diabetes had lower rates of nephropathy than non-migrants 
 Migrants had lower rates of diabetic macrovascular complications than non-migrants 
 Poorer glycemic control could explain the higher complication rates in non-migrants 
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